I 
113TH CONGRESS 
2D SESSION 
H. R. 5350 
To amend the Federal Insecticide, Fungicide, and Rodenticide Act to allow 
the marketing, distribution, or sale of solid antimicrobial copper alloys 
with certain claims, to amend the Federal Food, Drug, and Cosmetic 
Act to exclude certain solid antimicrobial copper alloys from regulation 
as drugs or devices, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 31, 2014 
Mr. LATTA (for himself and Mr. MURPHY of Pennsylvania) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committee on Agriculture, for a period to 
be subsequently determined by the Speaker, in each case for consider-
ation of such provisions as fall within the jurisdiction of the committee 
concerned 
A BILL 
To 
amend 
the 
Federal 
Insecticide, 
Fungicide, 
and 
Rodenticide Act to allow the marketing, distribution, or 
sale of solid antimicrobial copper alloys with certain 
claims, to amend the Federal Food, Drug, and Cosmetic 
Act to exclude certain solid antimicrobial copper alloys 
from regulation as drugs or devices, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Mar 15 2010 
02:13 Aug 13, 2014
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5350.IH
H5350
smartinez on DSK4TPTVN1PROD with BILLS
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Infection Reduction 
Labeling Act of 2014’’. 
SEC. 2. TREATMENT OF SOLID ANTIMICROBIAL COPPER AL-
LOYS UNDER FEDERAL INSECTICIDE, FUN-
GICIDE, AND RODENTICIDE ACT. 
Section 3 of the Federal Insecticide, Fungicide, and 
Rodenticide Act (7 U.S.C. 136a) is amended by adding 
at the end the following new subsection: 
‘‘(i) CLAIMS MADE FOR SOLID ANTIMICROBIAL COP-
PER ALLOYS.— 
‘‘(1) CERTAIN CLAIMS AUTHORIZED.—Notwith-
standing any other provision of this Act, solid anti-
microbial copper alloys, and products made from 
such alloys, may be marketed, distributed, or sold 
with labeling making claims regarding the microbial 
reduction or infection control efficacy of the alloys if 
the claims are consistent with the results of— 
‘‘(A) federally-funded clinical trials finding 
greater than 25 percent reductions in infection 
rate or 50 percent reductions in microbial bur-
den; or 
‘‘(B) federally-funded clinical trials finding 
statistically significant reductions in infection 
rate or microbial burden. 
VerDate Mar 15 2010 
02:13 Aug 13, 2014
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5350.IH
H5350
smartinez on DSK4TPTVN1PROD with BILLS
‘‘(2) SUBMISSION
OR
REVIEW
OF
EFFICACY 
DATA
WAIVED.—The registration of solid anti-
microbial copper alloys under this section shall not 
require submission or review of efficacy data related 
to claims consistent with the results of the clinical 
trials described in paragraph (1). 
‘‘(3) CONSISTENCY OF CLAIMS WITH AGENCY- 
REGISTERED PRODUCT LABEL.— 
‘‘(A) IN
GENERAL.—Claims described in 
paragraph (1) shall be consistent with the prod-
uct label registered under this section. 
‘‘(B) PROCESS FOR MODIFICATION OF LA-
BELING.—In lieu of the notification process 
under subsection (c)(9), registration of a solid 
antimicrobial copper alloy may be modified to 
ensure the consistency of claims described in 
paragraph (1) with the product labeling pursu-
ant to the following process: 
‘‘(i) The registrant shall submit a no-
tification identifying the proposed claims 
that are consistent with the results of the 
clinical trials described in paragraph (1), 
and include a copy of the proposed amend-
ed product label. 
VerDate Mar 15 2010 
02:13 Aug 13, 2014
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5350.IH
H5350
smartinez on DSK4TPTVN1PROD with BILLS
‘‘(ii) Within 30 days after receipt of 
such a notification, the Administrator 
shall— 
‘‘(I) notify the registrant in writ-
ing if the Administrator objects to any 
of the proposed claims as not con-
sistent with the results of the clinical 
trials described in paragraph (1); and 
‘‘(II) state the reasons why. 
‘‘(iii) A registrant may file a response 
to any such objection not later than 30 
days after the registrant’s receipt of the 
objection. 
‘‘(iv) After receipt and consideration 
of any such response, the Administrator 
shall issue a decision within 30 days. 
‘‘(v) A decision under clause (iv) shall 
be considered to be a final agency action. 
‘‘(vi) A registrant may distribute or 
sell a solid antimicrobial copper alloy prod-
uct with the claims described in paragraph 
(1) after 60 days of submission of the noti-
fication described in this subparagraph, 
unless the Administrator issues an objec-
tion as described in this subparagraph. 
VerDate Mar 15 2010 
02:13 Aug 13, 2014
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5350.IH
H5350
smartinez on DSK4TPTVN1PROD with BILLS
‘‘(4) DEFINITION.—In this subsection, the term 
‘solid antimicrobial copper alloy’ means a solid cop-
per alloy that— 
‘‘(A) is registered under this section; 
‘‘(B) is listed under Environmental Protec-
tion Agency registration number 82012–1, 
82012–2, 82012–3, 82012–4, 82012–5, or 
82012–6, or is otherwise identified by a Unified 
Numbering System code in an Environmental 
Protection Agency registration; 
‘‘(C) has a copper content of not less than 
60 weight percent; and 
‘‘(D) has a content of not more than 0.1 
weight percent of each of the following: lead, 
chromium, and arsenic.’’. 
SEC. 3. TREATMENT OF SOLID ANTIMICROBIAL COPPER AL-
LOYS UNDER FEDERAL FOOD, DRUG, AND 
COSMETIC ACT. 
Subchapter E of chapter V of the Federal Food, 
Drug, and Cosmetic Act is amended by inserting after sec-
tion 569C of such Act (21 U.S.C. 360bbb–8c) the fol-
lowing: 
‘‘SEC. 569D. SOLID ANTIMICROBIAL COPPER ALLOYS. 
‘‘(a) EXCLUSION FROM TREATMENT AS DRUG OR 
DEVICE.—A product that is made from solid antimicrobial 
VerDate Mar 15 2010 
02:13 Aug 13, 2014
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H5350.IH
H5350
smartinez on DSK4TPTVN1PROD with BILLS